NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in X Financial (or the “Company”) (NYSE:XYF) of the February 7, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in X Financial American Depositary Shares (“ADSs”) pursuant and/or traceable to the Company’s September 19, 2018 IPO (the “IPO”), and would like to discuss your legal rights, click here: www.faruqilaw.com/XYF.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it.. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of all those who acquired X Financial American Depositary Shares pursuant and/or traceable to the Company’s September 19, 2018 IPO. The case, Chen v. X Financial et al, No. 19-cv-06908 was filed on December 9, 2019.

The lawsuit focuses on whether the Company and its executives violated federal securities laws in the Company’s Registration Statement by making false and/or misleading statements and/or failing to disclose that: (1) the Company’s total loan facilitation amount was not growing, but rather was contracting; (2) the number of investors actively using X Financials’ platform was shrinking; (3) demand from SMEs for the Company’s preferred loans was plummeting; (4) the Company’s preferred loans had performed so poorly that it had begun drastically scaling back its preferred loans in the first quarter of 2018, several months before the IPO, and was in the process of phasing out such loans completely; (5) demand for the Company’s card loans was also plummeting; (6) the revenue and loan facilitation growth provided in the Registration Statement leading up to the IPO was achieved by relaxed credit and due diligence standards, under which the Company had underwritten tens of millions of dollars’ worth of poor quality loans that suffered from a disproportionately high risk of default as compared to the Company’s earlier loan vintages; (7) the Company was suffering from accelerated delinquency rates from poor quality loans that it had underwritten in the first, second, and third quarters of 2018, which had caused the Company’s delinquency rate to sharply rise; (8) the Company’s product mix had significantly deteriorated; (9) the Company’s net revenue was on track to decline by 22% during the third quarter of 2018; and (10) as a result, the Registration Statement was materially false and/or misleading and failed to state information required to be stated therein.

On November 22, 2019, X Financials’ ADSs closed at $1.74 per ADS. This price represented an 81.68% decline from the $9.50 per share price at which X Financials’ ADSs had been sold to the investing public in the IPO.

As of the date this complaint was filed, X Financials’ ADSs continue to trade below the $9.50 per share IPO price.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding X Financial’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its common stock at a price to the public of $23.00 per share. All of the shares are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,173,913 shares of its common stock. Before deducting the underwriting discounts and commissions and estimated offering expenses, Denali Therapeutics expects to receive total gross proceeds of approximately $180 million, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about January 31, 2020, subject to satisfaction of customary closing conditions.

Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies are acting as joint book-running managers and Nomura Securities International, Inc., H.C. Wainwright & Co. and Janney Montgomery Scott are acting as co-managers for the offering.

Denali Therapeutics filed a Registration Statement on Form S-3, which was automatically effective upon filing with the SEC on March 12, 2019, and has filed a preliminary prospectus supplement and accompanying prospectus relating to the offering on January 27, 2020. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov.

When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained from:

Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, fax: 212-902-9316, email: This email address is being protected from spambots. You need JavaScript enabled to view it.; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or by email: This email address is being protected from spambots. You need JavaScript enabled to view it.; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at This email address is being protected from spambots. You need JavaScript enabled to view it..

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About Denali Therapeutics

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the BBB for neurodegenerative diseases. Denali Therapeutics pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali Therapeutics is based in South San Francisco.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether or not Denali Therapeutics will be able to raise capital through the sale of shares of common stock or consummate the offering, the final terms of the offering, the satisfaction of customary closing conditions, prevailing market conditions, the anticipated use of the proceeds of the offering which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Additional risks and uncertainties relating to the offering, Denali Therapeutics and its business can be found under the heading “Risk Factors” in Denali Therapeutics’ most recent current, quarterly and annual reports filed with the SEC and in the preliminary prospectus supplement and accompanying prospectus relating to the offering to be filed with the SEC. Denali Therapeutics assumes no duty or obligation to update or revise any forward-looking statements for any reason.

CONTACT:

Lizzie Hyland
(646) 495-2706
This email address is being protected from spambots. You need JavaScript enabled to view it.

or

Morgan Warners
(202) 295-0124
This email address is being protected from spambots. You need JavaScript enabled to view it.                                            

WILMINGTON, Del., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating:

TD Ameritrade Holding Corporation (NASDAQ GS: AMTD) regarding possible breaches of fiduciary duties and other violations of law related to TD Ameritrade’s agreement to be acquired by The Charles Schwab Corporation.  Shareholders of TD Ameritrade will receive 1.0837 shares of Charles Schwab for each share of TD Ameritrade owned.  To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-td-ameritrade-holding-corporation.

Texas Capital Bancshares, Inc. (NASDAQ GS: TCBI) regarding possible breaches of fiduciary duties and other violations of law related to Texas Capital’s agreement to be acquired by Independent Bank Group, Inc. Shareholders of Texas Capital will receive 1.0311 shares of Independent Bank Group for each share of Texas Capital owned.  To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-texas-capital-bancshares-inc.

Care.com, Inc. (NYSE: CRCM) regarding possible breaches of fiduciary duties and other violations of law related to Care.com’s agreement to be acquired by IAC/InterActiveCorp. Shareholders of Care.com will receive $15.00 per share in cash for each share of Care.com owned. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-carecom-inc.

LogMeIn, Inc. (NASDAQ GS: LOGM) regarding possible breaches of fiduciary duties and other violations of law related to LogMeIn’s agreement to be acquired by affiliates of Francisco Partners and Evergreen Coast Capital Corporation. Shareholders of LogMeIn will receive $86.05 in cash for each share of LogMeIn owned. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-logmein-inc.

If you would like to discuss any of these investigations and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242 or by e-mail at This email address is being protected from spambots. You need JavaScript enabled to view it.. 

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.  Attorney advertising.  Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
Telephone: (302) 295-5310
Toll-Free: (888) 969-4242
Fax: (302) 654-7530
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
http://www.rigrodskylong.com
Follow Rigrodsky & Long on Facebook and Twitter

CHARLOTTE, N.C., Jan. 28, 2020 (GLOBE NEWSWIRE) -- The National Association of Home Builders (NAHB) named Crescent Communities the 2019 Multifamily Development Firm of the Year during its annual International Builders’ Show, held January 21 in Las Vegas. NAHB’s Multifamily Pillars of the Industry Awards highlight the year’s top creative development concepts, innovative financing strategies, great design, and superior management and marketing in the apartment and condominium marketplace.

“We are honored to receive this prestigious award from the National Association of Home Builders,” said President and Chief Operating Officer Brian Natwick. “This achievement is a direct result of the extraordinary leadership of our team at Crescent Communities who are committed to innovation, curiosity, integrity, and excellence. These values guide everything we do, and we are humbled to be recognized for our work during this past year.”

Since 2011, Crescent Communities has experienced significant growth by investing nearly $4.0 billion and expanding across 12 markets and seven offices. The multifamily portfolio includes 15,000 units and 432,000 SF of retail completed or under construction representing a total investment of $3.3 billion. The commercial portfolio includes 3.2 million SF of office, industrial and retail completed or under construction representing a total investment of $650 million. With a focus on sustainable development practices, the company pursues LEED certification for commercial spaces and NGBS certification for multifamily residences.  

Natwick, who joined Crescent Communities in 2006, has played a vital role in the growth and success of the company’s multifamily business. Prior to his current position as President and Chief Operating Officer, he served as President of the multifamily business since 2011. He championed the creation of NOVEL by Crescent Communities multifamily brand and extended the company’s footprint from the southeast to western markets including Dallas, Houston, Denver, Phoenix, and Salt Lake City.

Additional accolades for Crescent Communities included NOVEL South Capital winning Best Overall Leasing or Sales Campaign for a Multifamily Community, NOVEL Bishop Arts being named a finalist for Best Interior Merchandising of a Common Area, and NOVEL Rio being named a finalist for Best Low-Rise Apartment Community. For more information, please visit www.crescentcommunities.com.

About Crescent Communities
Crescent Communities is a nationally recognized, market-leading real estate investor, developer and operator of mixed-use communities. We create high-quality, differentiated multifamily and commercial communities in many of the fastest growing markets in the United States. Since 1963, our development portfolio has included more than 59 multifamily communities, 21 million square feet of commercial space and 60 single family master-planned communities. Headquartered in Charlotte, Crescent Communities has regional offices in Washington, DC, Atlanta, Orlando, Nashville, Dallas, and Denver. Our multifamily communities are branded NOVEL by Crescent Communities.

Media Contact
Lisa Richards
Crescent Communities
704-964-9578
This email address is being protected from spambots. You need JavaScript enabled to view it.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b4cd4eb2-7eb3-4b8c-b6d6-c0cf464147ce
https://www.globenewswire.com/NewsRoom/AttachmentNg/698aba29-95bb-4c57-87a6-3c806128360b

NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) common stock between March 19, 2018 and September 26, 2018, inclusive (the “Class Period”).

All investors who purchased shares of Geron Corporation and incurred losses are urged to contact the firm immediately at This email address is being protected from spambots. You need JavaScript enabled to view it. or (800) 575-0735 or (212) 545-4774. You may obtain additional information and join the action on our website, www.whafh.com.

If you have incurred losses in the shares of Geron Corporation, you may, no later than March 23, 2020, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of Geron Corporation.

## Click here to join the action. ##

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

On March 27, 2018, STAT published a report revealing that the Company’s recent stock performance was due to “flimsy” claims in connection to the efficacy of imetelstat, Geron’s experimental myelofibrosis treatment. STAT stated that the available data for imetelstat undercuts Geron’s representations as to the drug’s efficacy.

On this news, Geron’s share price fell $1.75, or over 29%, over two consecutive trading sessions to close at $4.23 per share on March 27, 2018, thereby injuring investors.

Subsequently, on September 27, 2018, Geron disclosed its Phase 2 study results for imetelstat failed to meet its primary efficacy endpoints. On this news, Geron’s share price fell $3.92, or over 62%, to close at $2.31 per share on September 27, 2018.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at This email address is being protected from spambots. You need JavaScript enabled to view it., or visit our website at www.whafh.com to join this action.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.